Early blastic transformation with CNS infiltration in a patient with chronic myeloid leukaemia treated with imatinib.
Pavlu
Jiri
J
Hillingdon Hospital, Uxbridge, UK. pavluj@yahoo.com
Czepulkowski
Barbara
B
Kaczmarski
Richard
R
Jan-Mohamed
Riaz
R
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D001752:Blast Crisis; D001766:Blindness / Q000209:etiology; D002490:Central Nervous System / Q000473:pathology*; D002879:Chromosomes, Human, Pair 10 / Q000235:genetics; D002888:Chromosomes, Human, Pair 19 / Q000235:genetics; D002896:Chromosomes, Human, Pair 6 / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D017254:Leukemic Infiltration; D008297:Male; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D012160:Retina / Q000473:pathology; D014314:Trisomy
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate